Loading your page…
Loading your page…
Published by European Association for the Study of Diabetes · 44 pages · Class I–II
Joint ADA/EASD consensus prioritises cardiovascular risk, heart failure, and CKD as drivers of drug choice over glycaemic control alone. GLP-1 RAs and SGLT2-i move to second-line regardless of HbA1c when CV disease, HF or CKD is present. Personalised HbA1c targets 6.5–8.0% based on patient profile.
Create a free Prognia account to read the complete guideline — including all recommendations, evidence tables, drug dosing, and clinical pearls.
Free plan includes 10 guideline reads per day · No credit card required